Psychedelics Company Silo Wellness Expands its Shareholder Base to Europe by Commencing Trading on the German Börse Frankfurt (FRA) Exchange Under Ticker Symbol “3K70”

Silo Wellness Inc. (CSE: SILO) (FRA:3K70), a wellness company in the psychedelics and functional mushroom markets, is delighted to announce the expanded trading of its common shares, which now includes an overseas listing on the German Börse Frankfurt (FRA) exchange platform.

Silo Wellness securities commenced trading on the FRA on Friday, April 9, 2021, under the ticker symbol 3K70 and registered under WKN: A2QQTP and/or ISIN: CA8271241082.

Douglas K. Gordon, Chief Executive Officer of Silo Wellness, noted that this expansion into the European market marks a significant milestone for the company. It broadens the company’s international presence and enables a wider audience of investors to participate in the growth of Silo Wellness. The company aims to continue delivering on its mission and to grow on a global scale.

About Silo Wellness: The mission of Silo Wellness is to improve health and wellness by developing and introducing psychedelic medicine. It seeks to reduce trauma and increase performance by destigmatizing the active compounds in psychedelics and innovating the ease of administration and ingestion. Silo Wellness aims to introduce new, safe, and affordable alternatives to current medicines. This will be accomplished by facilitating entry into new and emerging markets where psychedelics are legal, conducting ketamine and psilocybin wellness retreats, and manufacturing and distributing functional mushrooms.

Silo Wellness’ activities since its inception have focused on the development of psilocybin-free functional mushroom tinctures, the formulation of a psilocybin nasal spray in Jamaica, and the offering of Jamaican and Oregon psychedelic wellness retreats, along with the cultivation of psychedelic mushrooms in Jamaica. Please note that none of Silo Wellness’ products claim to cure or mitigate any physical or mental disease, symptoms, disorders, or abnormalities.

For further information, please contact Silo Wellness Investor Relations: (604) 343-2724, [email protected]. Media Relations: [email protected].

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains forward-looking information and statements within the meaning of the applicable Canadian securities legislation. These statements are based on expectations, estimates, and projections as of the date of this news release. In this release, forward-looking statements relate to the listing of the common shares of Silo Wellness on the CSE and the company’s business plans. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update these statements should they change, except as required by law.

More Press